Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.

J Natl Cancer Inst 2018 12;110(12):1370-1379

Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.

Background: Radiotherapy after breast conservation has become the standard of care. Prior meta-analyses on effects of radiotherapy predated availability of gene expression profiling (GEP) to assess recurrence risk and/or did not include all relevant outcomes. This analysis used GEP information with pooled individual-level data to evaluate the impact of omitting radiotherapy on recurrence and mortality.

Methods: We considered trials that evaluated or administered radiotherapy after lumpectomy in women with low-risk breast cancer. Women included had undergone lumpectomy and were treated with hormonal therapy for stage I, ER+ and/or PR+, HER2- breast cancer with Oncotype scores no greater than 18. Recurrence-free interval (RFI), type of RFI (locoregional or distant), and breast cancer-specific and overall survival were compared between no radiotherapy and radiotherapy using adjusted Cox models. All statistical tests were two-sided.

Results: The final sample included 1778 women from seven trials. Omission of radiotherapy was associated with an overall adjusted hazard ratio of 2.59 (95% confidence interval [CI] = 1.38 to 4.89, P = .003) for RFI. There was a statistically significant increase in any first locoregional recurrence (P = .001), but not distant recurrence events (P = .90), or breast cancer-specific (P = .85) or overall survival (P = .61). Five-year RFI rate was high (93.5% for no radiotherapy vs 97.9% for radiotherapy; absolute reduction = 4.4%, 95% CI = 0.7% to 8.1%, P = .03). The effects of radiotherapy varied across subgroups, with lower RFI rates for those with Oncotype scores of less than 11 (vs 11-18), older (vs younger), and ER+/PR+ status (vs other).

Conclusions: Omission of radiotherapy in hormone-sensitive patients with low recurrence risk may lead to a modest increase in locoregional recurrence event rates, but does not appear to increase the rate of distant recurrence or death.

Download full-text PDF

http://dx.doi.org/10.1093/jnci/djy128DOI Listing
December 2018
18 Reads

Publication Analysis

Top Keywords

effects radiotherapy
breast cancer
recurrence risk
breast cancer-specific
oncotype scores
locoregional recurrence
distant recurrence
increase locoregional
omission radiotherapy
women trials
1778 women
ratio 259
hazard ratio
trials omission
associated adjusted
adjusted hazard


(Supplied by CrossRef)
Cancer treatment and survivorship statistics, 2016
Miller et al.
CA Cancer J Clin 2016
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials
Darby et al.
Lancet 2011
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: Long-term follow-up of CALGB 9343
Hughes et al.
J Clin Oncol 2013
Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials
Taylor et al.
J Clin Oncol 2017
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor–positive breast cancer: results from NSABP B-14 and NSABP B-20
Mamounas et al.
J Clin Oncol 2010
Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer
Fyles et al.
N Engl J Med 2004
Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence
Winzer et al.
Eur J Cancer 2010
Prospective validation of a 21-gene expression assay in breast cancer
Sparano et al.
N Engl J Med 2015
Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less
Fisher et al.
J Clin Oncol 2002
A Randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor–positive tumors
Fisher et al.
N Engl J Med 1989
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
Fisher et al.
J Natl Cancer Inst 1997

Similar Publications